Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s492, 2024. DOI: 10.25251/skin.8.supp.492. Disponível em: https://skin.dermsquared.com/skin/article/view/3138. Acesso em: 18 may. 2025.